"The US Food and Drug Administration (FDA) today approved asfotase alfa (Strensiq, Alexion Pharmaceuticals) as the first-ever therapy for patients who develop hypophosphatasia, a rare metabolic bone disorder, in childhood.
The health-care provider should instruct patients to report to the health-care provider adverse events such as vesiculation, ulceration or necrosis which may appear at the test site in highly sensitive patients. The health-care provider should also inform the patient that pain, pruritus and discomfort at the site may also occur.
The health-care provider should inform the patient of the need to return for the reading of the test. Self reading of the test has been shown to be unreliable.24 The health-care provider should inform the patient of the need to maintain a personal immunization record.
24. APIC Guidelines Committee. APIC position paper: responsibility for interpretation of the PPD tuberculin skin test. Am J Infect Control 1999;27:56-58.
Last reviewed on RxList: 1/30/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Tubersol Information
Report Problems to the Food and Drug Administration
Find out what women really need.